Beta Bionics hit net sales of $44.7m in the first nine months of 2024, marking an increase from $3.6m in 2023. Beta Bionics’ ...

Beta Bionics has announced the pricing of its upsized initial public offering of 12 million shares of common stock at a price to the public of $17 per share.

Abbott Laboratories’ ABT growth in the fourth quarter of 2024 can be attributed to strong improvement in global Core ...

With a solid foundation for growth and a promising outlook, the global lancet market is on track to achieve its projected USD ...

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

Global healthcare leader Abbott has developed Ensure Gold, a science-based nutrition solution available in both powder and ...